TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
3D Medicines, Inc. ( (HK:1244) ) just unveiled an update.
3D Medicines Inc. has entered into a strategic cooperation agreement with CATUG Biotechnology to advance the development of TLNP-delivered in vivo CAR-T/NK therapies. This collaboration aims to combine 3D Medicines’ mRNA R&D platform and LNP delivery system with CATUG’s expertise in large-scale mRNA production, enhancing the company’s capabilities in targeted LNP delivery, cancer vaccines, and immune cell therapies. The agreement is expected to accelerate 3D Medicines’ expansion in mRNA research and support the clinical development and commercialization of its innovative therapeutic products.
The most recent analyst rating on (HK:1244) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.
More about 3D Medicines, Inc.
3D Medicines Inc. operates in the biotechnology industry, focusing on the development of mRNA technology and lipid nanoparticle (LNP) delivery systems. The company is known for its mRNA R&D platform and AI-enhanced LNP delivery technology, which are used in cancer vaccines and immune cell therapies.
Average Trading Volume: 551,053
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.17B
Find detailed analytics on 1244 stock on TipRanks’ Stock Analysis page.